Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
adenosine/schlaganfall
Der Link wird in der Zwischenablage gespeichert
Seite 1 von 25 Ergebnisse
Adenosine derivatives and methods of administration
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
The present invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
Publications in this area include WO 98/16539 (Novo Nordisk A/S) which describes adenosine derivatives for the treatment of
A.sub.3 adenosine receptor agonists and antagonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
Extracellular adenosine acts as a local modulator at four subtypes of adenosine receptors, namely, A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3, which are involved in numerous physiological and pathophysiological processes. Fredholm et al., Pharmacol. Rev. 2001; 53:527-52.
Purine derivatives as A3 and A1 adenosine receptor agonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
This invention pertains to A.sub.3 and A.sub.1 adenosine receptor agonists, pharmaceutical compositions comprising such agonists, and a method of use thereof, for example, in treating various medical disorders.
BACKGROUND OF THE INVENTION
Extracellular adenosine acts as a
Purine derivatives as A.sub.3 adenosine receptor-selective agonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
Extracellular adenosine acts as a local modulator at four subtypes of adenosine receptors, namely, A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3, which are involved in numerous physiological and pathophysiological processes. Fredholm et al., Pharmacol. Rev. 2001; 53:527-52.
Allosteric modulators of the A.sub.1 adenosine receptor
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
The present invention relates to 2-aminothiophene derivatives, pharmaceutical compositions containing them, and to methods of treating conditions mediated by the A.sub.1 adenosine receptor including pain, in particular, chronic pain such as neuropathic pain, cardiac disease or disorder such as
Allosteric modulators of the A.sub.1 adenosine receptor
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
The present invention relates to 2-aminothiophene derivatives, pharmaceutical compositions containing them, and to methods of treating conditions mediated by the A.sub.1 adenosine receptor including pain, in particular, chronic pain such as neuropathic pain, cardiac disease or disorder such as
Adenosine A.sub.2A receptor antagonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The present invention relates to novel triazolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of treating conditions and diseases mediated by the adenosine A.sub.2A receptor activity, by employing such compounds.
BACKGROUND OF THE
Use of selective adenosine A.sub.1 receptor allosteric enhancers to manipulate angiogenesis
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
The instant invention relates generally to methods of manipulating angiogenesis and more specifically it relates to the use of compounds which are selective adenosine A.sub.1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis in animal subjects. These
Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
This invention pertains to N-piperazineacetamide derivatives of 4,5-diphenyl-oxazoles, thiazoles and imidazoles having drug and bio-affecting properties and to their preparation and use. In particular the compounds of this invention are novel adenosine reuptake inhibitors
Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
Extracellular adenosine acts as a local modulator at four subtypes of adenosine receptors, namely, A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3, which are involved in numerous physiological and pathophysiological processes. Fredholm et al., Pharmacol. Rev. 2001; 53:527-52.
Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A.sub.2A receptor activity
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
FIELD OF THE INVENTION
The present invention relates to novel triazolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of treating conditions and diseases mediated by the adenosine A.sub.2A receptor activity, by employing such compounds.
BACKGROUND OF THE
Adenosine receptor agonists, partial agonists, and antagonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the
A.sub.3 adenosine receptor antagonists and partial agonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND OF THE INVENTION
There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the
Adenosine A2a receptor antagonists
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
This invention relates to substituted 1,2,4-triazolo[1,5-c]pyrimidine adenosine A.sub.2a receptor antagonists, the use of said compounds in the treatment of central nervous system diseases, in particular Parkinson's disease, and to pharmaceutical compositions containing said
Pyrazine derivatives and pharmaceutical use thereof
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
TECHNICAL FIELD
The present invention relates to a novel pyrazine derivative and a salt thereof, which are useful as medicaments.
BACKGROUND ART
Adenosine is a ubiquitous biochemical messenger. Adenosine binds to and activates seven-transmembrane spanning G-protein coupled receptors, eliciting a
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
